Overview

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Status:
Completed

Trial end date:
2020-11-25

Target enrollment:

Participant gender:

Summary

This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics in patients with advanced solid tumor followed by an expansion phase in patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab